Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by PAMELA THERESE SOLIMAN and SHANNON NEVILLE WESTIN.
PAMELA THERESE SOLIMAN
Connection Strength
5.272
SHANNON NEVILLE WESTIN
  1. Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol. 2014 Sep; 134(3):546-51.
    View in: PubMed
    Score: 0.485
  2. Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study. Gynecol Oncol. 2022 Dec; 167(3):452-457.
    View in: PubMed
    Score: 0.215
  3. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
    View in: PubMed
    Score: 0.199
  4. Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. Int J Gynecol Cancer. 2021 02; 31(2):232-237.
    View in: PubMed
    Score: 0.188
  5. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
    View in: PubMed
    Score: 0.185
  6. Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: surgical outcomes and hospital charges. Int J Gynecol Cancer. 2020 03; 30(3):352-357.
    View in: PubMed
    Score: 0.177
  7. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clin Cancer Res. 2020 02 01; 26(3):581-587.
    View in: PubMed
    Score: 0.175
  8. Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study. Cancer. 2019 10 01; 125(19):3347-3353.
    View in: PubMed
    Score: 0.171
  9. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380.
    View in: PubMed
    Score: 0.162
  10. The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer. J Gynecol Oncol. 2018 Sep; 29(5):e68.
    View in: PubMed
    Score: 0.158
  11. Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol. 2018 06; 149(3):484-490.
    View in: PubMed
    Score: 0.157
  12. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol. 2018 01; 131(1):109-116.
    View in: PubMed
    Score: 0.154
  13. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol. 2017 08; 146(2):234-239.
    View in: PubMed
    Score: 0.148
  14. Factors prognostic of survival in advanced-stage uterine serous carcinoma. Gynecol Oncol. 2017 07; 146(1):27-33.
    View in: PubMed
    Score: 0.147
  15. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study. Gynecol Oncol. 2016 Dec; 143(3):466-471.
    View in: PubMed
    Score: 0.142
  16. Role of Indocyanine Green in Sentinel Node Mapping in Gynecologic Cancer: Is Fluorescence Imaging the New Standard? J Minim Invasive Gynecol. 2016 Feb 01; 23(2):186-93.
    View in: PubMed
    Score: 0.133
  17. Impact of Lymph Node Ratio and Adjuvant Therapy in Node-Positive Endometrioid Endometrial Cancer. Int J Gynecol Cancer. 2015 Oct; 25(8):1437-44.
    View in: PubMed
    Score: 0.132
  18. Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecol Oncol. 2015 Sep; 138(3):727-30.
    View in: PubMed
    Score: 0.130
  19. Position-related injury is uncommon in robotic gynecologic surgery. Gynecol Oncol. 2014 Dec; 135(3):534-8.
    View in: PubMed
    Score: 0.124
  20. Conversion from robotic surgery to laparotomy: a case-control study evaluating risk factors for conversion. Gynecol Oncol. 2014 Aug; 134(2):238-42.
    View in: PubMed
    Score: 0.121
  21. Pelvic exenteration: impact of age on surgical and oncologic outcomes. Gynecol Oncol. 2014 Jan; 132(1):114-8.
    View in: PubMed
    Score: 0.116
  22. Successful incorporation of robotic surgery into gynecologic oncology fellowship training. Gynecol Oncol. 2013 Dec; 131(3):730-3.
    View in: PubMed
    Score: 0.115
  23. The effect of body mass index on surgical outcomes and survival following pelvic exenteration. Gynecol Oncol. 2012 May; 125(2):336-42.
    View in: PubMed
    Score: 0.102
  24. Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: an analysis of surgical outcomes. Gynecol Oncol. 2012 Apr; 125(1):252-5.
    View in: PubMed
    Score: 0.101
  25. Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. Gynecol Oncol. 2011 Nov; 123(2):333-6.
    View in: PubMed
    Score: 0.099
  26. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer. 2011 Jun 15; 117(12):2659-67.
    View in: PubMed
    Score: 0.095
  27. Translating biological insights into improved management of endometrial cancer. Nat Rev Clin Oncol. 2024 Nov; 21(11):781-800.
    View in: PubMed
    Score: 0.061
  28. Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers. Clin Cancer Res. 2024 Jul 15; 30(14):2986-2995.
    View in: PubMed
    Score: 0.061
  29. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071.
    View in: PubMed
    Score: 0.058
  30. Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes. Gynecol Oncol. 2022 07; 166(1):50-56.
    View in: PubMed
    Score: 0.052
  31. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021 07; 162(1):24-31.
    View in: PubMed
    Score: 0.049
  32. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71.
    View in: PubMed
    Score: 0.048
  33. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. 2021 04; 161(1):104-112.
    View in: PubMed
    Score: 0.048
  34. An Integrated Approach to Selecting a Prepared Medical Decision-Maker. J Pain Symptom Manage. 2021 06; 61(6):1305-1310.
    View in: PubMed
    Score: 0.047
  35. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer. 2021 01; 31(1):92-97.
    View in: PubMed
    Score: 0.047
  36. Systematic Approach to Selecting and Preparing a Medical Power of Attorney in the Gynecologic Oncology Center. J Oncol Pract. 2019 12; 15(12):e1092-e1097.
    View in: PubMed
    Score: 0.044
  37. Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. Gynecol Oncol. 2019 08; 154(2):328-332.
    View in: PubMed
    Score: 0.043
  38. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecol Oncol. 2019 07; 154(1):22-28.
    View in: PubMed
    Score: 0.042
  39. Prognostic factors impacting survival in early stage uterine carcinosarcoma. Gynecol Oncol. 2019 01; 152(1):31-37.
    View in: PubMed
    Score: 0.041
  40. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol. 2018 12; 151(3):428-432.
    View in: PubMed
    Score: 0.041
  41. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554.
    View in: PubMed
    Score: 0.040
  42. Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer. Oncotarget. 2018 Aug 17; 9(64):32321-32330.
    View in: PubMed
    Score: 0.040
  43. Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. Obstet Gynecol. 2018 07; 132(1):52-58.
    View in: PubMed
    Score: 0.040
  44. Ultrastaging of Sentinel Lymph Nodes in Endometrial Carcinoma According to Use of 2 Different Methods. Int J Gynecol Pathol. 2018 May; 37(3):242-251.
    View in: PubMed
    Score: 0.039
  45. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol Oncol. 2017 04; 145(1):55-60.
    View in: PubMed
    Score: 0.036
  46. Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. Gynecol Oncol. 2015 Jan; 136(1):48-53.
    View in: PubMed
    Score: 0.031
  47. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence. Gynecol Oncol. 2014 Dec; 135(3):455-61.
    View in: PubMed
    Score: 0.031
  48. Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia. Gynecol Oncol. 2014 Dec; 135(3):451-4.
    View in: PubMed
    Score: 0.031
  49. Minimally invasive surgery for endometrial cancer: does operative start time impact surgical and oncologic outcomes? Gynecol Oncol. 2014 Aug; 134(2):248-52.
    View in: PubMed
    Score: 0.030
  50. Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer. Curr Pharm Des. 2014; 20(11):1655-63.
    View in: PubMed
    Score: 0.029
  51. A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma. Gynecol Oncol. 2014 Feb; 132(2):366-71.
    View in: PubMed
    Score: 0.029
  52. Incidence of trocar site herniation following robotic gynecologic surgery. Gynecol Oncol. 2013 Nov; 131(2):400-3.
    View in: PubMed
    Score: 0.029
  53. Postoperative outcomes after continent versus incontinent urinary diversion at the time of pelvic exenteration for gynecologic malignancies. Gynecol Oncol. 2013 Jun; 129(3):580-5.
    View in: PubMed
    Score: 0.028
  54. The role of mucoregulatory agents after continence-preserving urinary diversion surgery. Am J Health Syst Pharm. 2012 Mar 15; 69(6):483-6.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.